Table 1.
Baseline clinical characteristics of patients treated with lenvatinib
| Lenvatinib (n=62) | |
|---|---|
| Age (years), median (range) | 74 (49–93) |
| Age group (years) | |
| <65 | 10 (16%) |
| ≥65 to <75 | 22 (36%) |
| ≥75 | 30 (48%) |
| Gender: male/female (%) | 53 (85%)/9 (15%) |
| Bodyweight (kg) | |
| <60 | 30 (48%) |
| ≥60 | 32 (52%) |
| Etiology of chronic liver disease | |
| HBV | 12 (19%) |
| HCV | 30 (48%) |
| Alcohol | 8 (13%) |
| Others | 12 (19%) |
| Child–Pugh class | |
| A | 54 (87%) |
| B | 8 (13%) |
| ECOG PS | |
| 0 | 42 (68%) |
| 1 | 20 (32%) |
| BCLC | |
| B (intermediate stage) | 25 (40%) |
| C (advanced stage) | 37 (60%) |
| Extrahepatic spread | |
| Yes | 26 (42%) |
| No | 36 (58%) |
| Macroscopic vascular invasion | |
| Yes | 17 (27%) |
| No | 45 (73%) |
| Baseline AFP concentration | |
| Median | 113.1 (1.6–70 000) |
| Baseline AFP concentration group (ng/mL) | |
| <200 | 34 (55%) |
| ≥200 | 27 (44%) |
| Missing | 1 (1%) |
| Concomitant systemic antiviral therapy for HBV or HCV | 19 (31%) |
| Clinical course (systemic therapy) | |
| First line | 39 (63%) |
| Second line | 6 (10%) |
| Third line | 17 (27%) |
| Median LEN treatment duration (days) | 156.5 (30–662) |
AFP, alpha‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; LEN, lenvatinib; PS, performance status.